Format

Send to:

Choose Destination
See comment in PubMed Commons below
Hum Vaccin. 2006 Mar-Apr;2(2):68-73. Epub 2006 Mar 14.

Modeling future changes to the meningococcal serogroup C conjugate (MCC) vaccine program in England and Wales.

Author information

  • 1Immunisation Department, Health Protection Agency Centre for Infections, London, UK. caroline_trotter@yahoo.co.uk

Abstract

The UK meningococcal serogroup C conjugate (MCC) vaccine program has successfully controlled serogroup C disease, due to high vaccine effectiveness and substantial herd immunity. However, children immunised at 2, 3 and 4 months of age receive only short-term direct protection and may be at risk of disease 15 months after vaccination. To investigate this we applied a mathematical model to predict the future epidemiology of serogroup C disease, with and without changes to the immunization schedule. Only a few cases of serogroup C disease were predicted to occur over the next few years because of persisting herd immunity, even without a change to the vaccine schedule. The inclusion of a booster dose is likely to improve the impact of the MCC program and reducing the number of doses in infancy will improve cost-effectiveness and create space in the schedule for the addition of other vaccines.

PMID:
17012888
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk